1. Discuss the role of TDM1 and anthracyclines for the treatment of Her2 positive breast cancer

2. Discuss the role of maintenance capecitabine in TNBC

3. Outline the long term results of the MINDACT study 

4. Discuss checkpoint inhibitors in metastatic TNBC

5. Identify PARP inhibitors in non-germline BRCA mutation carriers with metastatic breast cancer

6. Discuss impact of JCOG1008 on decision for weekly versus q3 weekly concurrent cisplatin in the adjuvant chemoradiation.

   7. Discuss the data supporting local radiation therapy in patients with EGFR mutated lung cancer.

   8. Discuss the results of the RAPIDO trial and its impact on neoadjuvant therapy for rectal cancer

WebEx Event link for attendees: https://uwmadison.webex.com/uwmadison/onstage/g.php?MTID=e4f76229fa1cef9d45701625f6361eaf2

Session date: 
09/16/2020 - 8:00am to 9:00am CDT
Clinical Science Center, G5/119
600 Highland Ave
Madison, WI 53792
United States
  • 1.00 ACPE Contact Hours - Pharmacist
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC Contact Hours
  • 1.00 University of Wisconsin–Madison Continuing Education Hours

Please login or register to take this course.
Discloser List CME Internal Report
Dr. Kari Wisinski
Dr. Adam Burr
Dr. Elisavet Paplomata